MRKR — Marker Therapeutics, Inc.
$0.87
$-0.03 (-3.33%)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Market Cap
$14.51M
Forward P/E
-1.6x
52-Week Range
N/A
MRKR Price History
Revenue vs. Net Income
$3.5M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$12M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-74.0%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
8.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
54.9%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+70.5%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
